Theorem Clinical Research

Drug Sponsors

Allergan adopts one-year stockholder rights plan

Wednesday, April 23, 2014 02:16 PM

Irvine, Calif.-based Allergan has announced its board of directors has unanimously adopted a one-year stockholder rights plan effective April 22, and declared a dividend distribution of one preferred share purchase right on each outstanding share of the company's common stock.

More... »


Bio-Techne to acquire Shanghai PrimeGene Bio-Tech

Wednesday, April 16, 2014 01:40 PM

Techne, a developer, manufacturer and seller of biotechnology products and clinical controls, has announced that its R&D systems China subsidiary, a specialty manufacturer of biological products, has entered into an agreement to acquire 100% of Shanghai PrimeGene Bio-Tech.

More... »


BioAlliance Pharma, Topotarget to merge

Wednesday, April 16, 2014 01:18 PM

BioAlliance Pharma, an innovative company specialized in developing drugs within orphan oncology diseases, and Topotarget, a Scandinavian-based biopharmaceutical company, intend to merge to create an orphan oncology company with highly complementary pipelines of late-stage products addressing significant unmet medical needs.

More... »

Scripps Research Institute launches drug discovery initiative Scripps Advance

Monday, April 14, 2014 03:02 PM

The Scripps Research Institute (TSRI) has announced the formation of Scripps Advance, a new drug discovery initiative to translate early-stage biomedical research projects, both internal and external to TSRI, into clinical development candidates. Scripps Advance's first collaborator in this new endeavor is the Johnson & Johnson Innovation Center in California.

More... »

NeoStem to acquire California Stem Cell

Monday, April 14, 2014 03:01 PM

NeoStem, a provider of emerging cellular therapy, has entered into a definitive agreement to acquire California Stem Cell (CSC), an Irvine, Calif.-based stem cell biotechnology company. NeoStem plans to initiate a pivotal phase III trial of Melapuldencel-T, an autologous melanoma initiating (stem) cell immune-based therapy intended to eliminate the tumor cells capable of causing disease recurrence.

More... »

PHARMAC promotes competition to improving patient access to high-cost medicines

Thursday, April 10, 2014 01:55 PM

PHARMAC has announced its intention to test out a contestable fund for high-cost medicines for rare disorders, which could be seeking proposals from pharmaceutical companies by the end of 2014. Promoting competition among suppliers could be the key to improving patients’ access to high-cost medicines for rare disorders, said chief executive Steffan Crausaz. The fund is a response to concerns about access to these medicines that PHARMAC has been hearing from patients through forums and consultations in recent months.

More... »

Roche acquires IQuum to strengthen offerings in molecular diagnostics

Wednesday, April 9, 2014 12:40 PM

Roche has acquired IQuum, a privately held company focused on developing point-of-care offerings for the molecular diagnostics market. Roche will pay IQuum shareholders $275 million upfront and up to $175 million in contingent product-related milestones.

More... »

TetraLogic to acquire Shape Pharmaceuticals

Wednesday, April 9, 2014 12:25 PM

TetraLogic Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, will acquire Shape Pharmaceuticals, a privately held biotechnology company developing suberohydroxamic acid phenyl ester (SHAPE), a novel, tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA Cutaneous T-Cell Lymphoma (CTCL), adding a second clinical-stage oncology compound to the TetraLogic portfolio.

More... »

Mallinckrodt acquires Questcor for $5.6 billion

Monday, April 7, 2014 01:17 PM

By Ronald Rosenberg
CenterWatch Staff Writer

Fulfilling a strategy to substantially invest in the specialty pharmaceutical business, Mallinckrodt announced this morning it has entered into a definitive merger agreement with Questcor Pharmaceuticals, a high-growth biopharmaceutical company, in a transaction valued at about $5.6 billion.

More... »

Sun Pharma to acquire Ranbaxy for $4 billion

Monday, April 7, 2014 12:31 PM

India-based Sun Pharma, an international, integrated, specialty pharmaceutical company, will acquire Ranbaxy Laboratories, an integrated, research-based, international pharmaceutical company, in an all-stock transaction.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 2

Roche's $8.3B InterMune buy continues its buying spree with 'bolt-on' deal, fueling record M&A activity

FDA action plan seeks to close gap in women and minority patient representation in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs